Long after news broke that the White House was withdrawing its FDA commissioner nominee at the 11th hour, the reasons for that decision remain ... murky.
https://t.co/WfmgbN1srs
BeOne Medicines and Jiangsu Hengrui are China's top drugmakers. One built a global sales operation, while the other became a major partner for Western pharma. Their contrasting strategies reveal how China's biotech industry is gaining influence.
The head of the NSF, Cassidy told reporters, has to “show a certain amount of independence” should an administration press for “something which is not appropriate.”
“There was concern whether Jim would be that person,” he said.
w/ @MargaretManto
https://t.co/aAgLwUuQIz
Many science advocates celebrated the blue wave ushering Democrats into power. They are also losing a prominent and influential advocate for funding on the Hill at the same time, @AnilOza16 and @john_wilkerson note.
https://t.co/5gt612oLcR
NEW: It is no surprise but it is now official: U.S. loses measles elimination status, marking embarrassing stain on its public health record.
https://t.co/DJ19YTX3aX
New: The appointment of Stephen Miller as CoS has completely renewed RFK Jr.'s Make America Healthy Again agenda — and he's expected to go even harder on vaccines, people tell me.
"It feels like day one again."
https://t.co/dlPlLRWTCw
Today @statnews, in partnership with @WirescreenAI, launched a new index ranking the 25 most valuable publicly traded Chinese drugmakers. U.S. biotech and pharma companies are increasingly paying attention to these firms — and so are we.
https://t.co/Pj1qm0xmCP
Still not sure I follow this metaphor from @AbdulElSayed about his approach to RFK Jr. but I commend @NicholasFlorko for the follow-up question.
https://t.co/Wyk52LZLdu
New: Members of a little-known but influential panel of experts picked by RFK Jr. to recommend which preventive services insurers must cover have major conflicts of interests and could stand to gain $$ from the decisions they make: https://t.co/EMdp0Fa2zv
Quite a read from @bobjherman, who documents a new tactic in the war over out-of-network health care bills: Providers are suing employers.
https://t.co/NHfZp5YdLL
Something you might've missed last week: Liver docs from around the world got together to come up with a shared definition of a common and potentially fatal liver complication.
More here: https://t.co/BGCh30BRBy
After more than a year fiercely defending the Trump administration's actions, Calley Means castigates White House officials as bending to industry
https://t.co/ZCw0FivanJ
Smart story from @Jasonmmast of @statnews: For two decades, researchers debated whether a common gene therapy tool could in certain cases drive tumors. That debate is now over.
https://t.co/agAh7GHdCX